NasdaqCM - Nasdaq Real Time Price USD

Adverum Biotechnologies, Inc. (ADVM)

3.1200

+0.1200

+(4.00%)

At close: 4:00:01 PM EDT

3.1200

0.00

(0.00%)

After hours: 4:05:13 PM EDT

3 Penny Stocks Under $300M Market Cap To Consider

Over the last 7 days, the United States market has risen by 2.2%, and in the past year, it has climbed 8.2%, with earnings expected to grow by 14% per annum in the coming years. For investors willing to explore beyond well-known companies, penny stocks—often representing smaller or newer firms—can present intriguing possibilities. Although "penny stock" might seem like an outdated term, these investments remain relevant today as they offer opportunities for growth when backed by strong...

Simply Wall St. 2 days ago

VNDA

MYPS

MYPSW
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees enterin

GlobeNewswire 6 days ago

ADVM
+4.00%
Adverum Biotechnologies: Q4 Earnings Snapshot

REDWOOD CITY, Calif. AP) — Adverum Biotechnologies Inc. ADVM) on Tuesday reported a loss of $40.9 million in its fourth quarter.

Associated Press Finance 23 days ago

ADVM
+4.00%
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-

GlobeNewswire 23 days ago

ADVM
+4.00%
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance

GlobeNewswire last month

ADVM
+4.00%
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the Investors sec

GlobeNewswire last month

ADVM
+4.00%
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLO

GlobeNewswire 2 months ago

ADVM
+4.00%
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A r

GlobeNewswire 2 months ago

ADVM
+4.00%
3 US Penny Stocks With Market Caps Below $400M

As major U.S. stock indexes hover near record highs, investors are closely watching market movements and economic indicators for signs of future trends. For those interested in exploring smaller or newer companies, penny stocks—though an outdated term—remain a viable investment area with potential value. These stocks, often characterized by lower price points and the possibility of growth, can be particularly appealing when backed by strong financials and solid fundamentals. In this article,...

Simply Wall St. 2 months ago

NRDY

NMRA

ADVM
+4.00%
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s we

GlobeNewswire 2 months ago

ADVM
+4.00%
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee’s emp

GlobeNewswire 5 months ago

ADVM
+4.00%
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

PREMIUM
MT Newswires 5 months ago

ADVM
+4.00%
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

- 52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec - 6E10 dose in LUNA maintains visual and anatomic endpoints and demonstrates potential best-in-class injection-free rates and reduction in injection burden - No LUNA patients who received local steroid prophylaxis had inflammation at week 52 or at any subsequent visit, and 100% of OPTIC 2E11 patients were free of inflammation at year 1 and through yea

GlobeNewswire 5 months ago

ADVM
+4.00%
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, plans to host a webcast to report 52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data, and to provide key pivotal program design elements Mond

GlobeNewswire 5 months ago

ADVM
+4.00%
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

ADVM
+4.00%
Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM) on Monday reported a loss of $27.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $1.30. The results did not meet Wall Street expectations.

Associated Press Finance 5 months ago

ADVM
+4.00%
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard o

GlobeNewswire 5 months ago

ADVM
+4.00%
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr

GlobeNewswire 6 months ago

ADVM
+4.00%
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 6 months ago

ADVM
+4.00%
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic have been highlighted in this Screen of The Week article.

Zacks 7 months ago

ICCM

DRIO

WATT

Performance Overview

Return	ADVM	S&P 500 (^GSPC)
YTD	-33.19%	-3.70%
1-Year	-68.20%	+9.18%
3-Year	-69.41%	+37.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adverum Biotechnologies, Inc. (ADVM)

3 Penny Stocks Under $300M Market Cap To Consider

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

3 US Penny Stocks With Market Caps Below $400M

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Performance Overview